Rein Therapeutics receives Nasdaq delisting notice for bid price below $1.00

Rein Therapeutics, Inc.

• Received delisting notice from Nasdaq on Aug 21, 2026 for bid price below $1.00 for 30 consecutive trading days.
• Has 180 days, until Feb 17, 2027, to regain compliance with minimum bid price rule.
• Must achieve closing bid of at least $1.00 for 10 consecutive business days to cure.
• May be eligible for additional time if meeting other Capital Market listing standards, but no assurance given.